Page 6 - Kymab Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kymab ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kymab Ltd Today - Breaking & Trending Today

Y-mAbs Therapeutics (NASDAQ:YMAB) Announces Earnings Results, Beats Expectations By $0.16 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) released its earnings results on Monday. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.16, Briefing.com reports. The company had revenue of $20.30 million during the quarter, compared to analysts’ expectations of $15.55 million. Y-mAbs Therapeutics had a negative net margin of […] ....

New York , United States , Millennium Management , Polar Capital Holdings Plc , Capital Management , Morgan Stanley , Blackrock Inc , Y Mabs Therapeutics Inc , Canaccord Genuity Group , Y Mabs Therapeutics Company Profile , Y Mabs Therapeutics , Get Rating , Abs Therapeutics , Capital Holdings Plc , Street Corp , Thomas Gad , Y Mabs Therapeutics Daily , Nasdaq Ymab ,

Analysts Issue Forecasts for Y-mAbs Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:YMAB)

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) – Investment analysts at Wedbush issued their FY2027 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a research report issued on Wednesday, May 10th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.42) per share for the year. Wedbush has a “Outperform” rating […] ....

New York , United States , York Life Investment Management , Canaccord Genuity Group , Y Mabs Therapeutics Inc , Morgan Stanley , Tower Research Capital , Russell Investments Group Ltd , Citigroup Inc , Connor Clark Lunn Investment Management Ltd , Y Mabs Therapeutics Company Profile , Y Mabs Therapeutics , Get Rating , Y Mabs Therapeutic , Abs Therapeutics , Abs Therapeutics Stock Down , Lunn Investment Management , Research Capital , Investments Group , New York Life Investment Management , Thomas Gad , Y Mabs Therapeutics Daily , Nasdaq Ymab , Earnings Estimates ,

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Hold" by Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has been assigned an average recommendation of “Hold” from the twelve ratings firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have assigned a buy recommendation to the company. The […] ....

New York , United States , Jpmorgan Chase Co , Swiss National Bank , Blackrock Inc , Y Mabs Therapeutics Inc , Rice Hall James Associates , Metlife Investment Management , Morgan Stanley , Y Mabs Therapeutics , Get Rating , Abs Therapeutics Trading Down , Abs Therapeutics , Hall James , National Bank , Life Investment Management , Thomas Gad , Y Mabs Therapeutics Daily , Nasdaq Ymab ,

Y-mAbs Therapeutics (YMAB) Set to Announce Quarterly Earnings on Monday

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) will be issuing its quarterly earnings data after the market closes on Monday, May 8th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link. Y-mAbs Therapeutics (NASDAQ:YMAB – Get […] ....

New York , United States , Y Mabs Therapeutics Company Profile , Algert Global , Pricet Rowe Associates Inc , Morgan Stanley , Y Mabs Therapeutics Inc , Charles Schwab Investment Management Inc , Y Mabs Therapeutics , Get Rating , Abs Therapeutics , Schwab Investment Management , Thomas Gad , Y Mabs Therapeutics Daily , Nasdaq Ymab ,

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Sees Significant Growth in Short Interest

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 2,500,000 shares, a growth of 26.9% from the March 15th total of 1,970,000 shares. Based on an average daily volume of 678,200 shares, the days-to-cover ratio is […] ....

New York , United States , Zurcher Kantonalbank Zurich Cantonalbank , Y Mabs Therapeutics Inc , Morgan Stanley , Y Mabs Therapeutics Company Profile , Principal Financial Group Inc , Y Mabs Therapeutics , Get Rating , Kantonalbank Zurich Cantonalbank , Financial Group , Retirement System , Jane Street Group , Abs Therapeutics , Thomas Gad , Y Mabs Therapeutics Daily , Nasdaq Ymab ,